Autologous Cell Therapy-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data
Report Summary
Autologous Cell Therapy-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Autologous Cell Therapy industry, standing on the readers? perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Autologous Cell Therapy 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Autologous Cell Therapy worldwide and market share by regions, with company and product introduction, position in the Autologous Cell Therapy market
Market status and development trend of Autologous Cell Therapy by types and applications
Cost and profit status of Autologous Cell Therapy, and marketing status
Market growth drivers and challenges
The report segments the global Autologous Cell Therapy market as:
Global Autologous Cell Therapy Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Autologous Cell Therapy Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Bone Marrow
Epidermis
Global Autologous Cell Therapy Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Neurology
Orthopedics
Cancer
Wound Healing
CVD
Autoimmune
Others
Global Autologous Cell Therapy Market: Manufacturers Segment Analysis (Company and Product introduction, Autologous Cell Therapy Sales Volume, Revenue, Price and Gross Margin):
BioTime, Inc.
BrainStorm Cell Therapeutics
Caladrius Biosciences, Inc.
Fibrocell Science, Inc.
Opexa Therapeutics, Inc.
Pharmicell Co., Inc.
Regeneus Ltd.
TiGenix NV
TxCell SA
U.S. Stem Cell, Inc.
Vericel Corporation
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Autologous Cell Therapy-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Autologous Cell Therapy industry, standing on the readers? perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Autologous Cell Therapy 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Autologous Cell Therapy worldwide and market share by regions, with company and product introduction, position in the Autologous Cell Therapy market
Market status and development trend of Autologous Cell Therapy by types and applications
Cost and profit status of Autologous Cell Therapy, and marketing status
Market growth drivers and challenges
The report segments the global Autologous Cell Therapy market as:
Global Autologous Cell Therapy Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Autologous Cell Therapy Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Bone Marrow
Epidermis
Global Autologous Cell Therapy Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Neurology
Orthopedics
Cancer
Wound Healing
CVD
Autoimmune
Others
Global Autologous Cell Therapy Market: Manufacturers Segment Analysis (Company and Product introduction, Autologous Cell Therapy Sales Volume, Revenue, Price and Gross Margin):
BioTime, Inc.
BrainStorm Cell Therapeutics
Caladrius Biosciences, Inc.
Fibrocell Science, Inc.
Opexa Therapeutics, Inc.
Pharmicell Co., Inc.
Regeneus Ltd.
TiGenix NV
TxCell SA
U.S. Stem Cell, Inc.
Vericel Corporation
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF AUTOLOGOUS CELL THERAPY
1.1 Definition of Autologous Cell Therapy in This Report
1.2 Commercial Types of Autologous Cell Therapy
1.2.1 Bone Marrow
1.2.2 Epidermis
1.3 Downstream Application of Autologous Cell Therapy
1.3.1 Neurology
1.3.2 Orthopedics
1.3.3 Cancer
1.3.4 Wound Healing
1.3.5 CVD
1.3.6 Autoimmune
1.3.7 Others
1.4 Development History of Autologous Cell Therapy
1.5 Market Status and Trend of Autologous Cell Therapy 2013-2023
1.5.1 Global Autologous Cell Therapy Market Status and Trend 2013-2023
1.5.2 Regional Autologous Cell Therapy Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Autologous Cell Therapy 2013-2017
2.2 Sales Market of Autologous Cell Therapy by Regions
2.2.1 Sales Volume of Autologous Cell Therapy by Regions
2.2.2 Sales Value of Autologous Cell Therapy by Regions
2.3 Production Market of Autologous Cell Therapy by Regions
2.4 Global Market Forecast of Autologous Cell Therapy 2018-2023
2.4.1 Global Market Forecast of Autologous Cell Therapy 2018-2023
2.4.2 Market Forecast of Autologous Cell Therapy by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Autologous Cell Therapy by Types
3.2 Sales Value of Autologous Cell Therapy by Types
3.3 Market Forecast of Autologous Cell Therapy by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Autologous Cell Therapy by Downstream Industry
4.2 Global Market Forecast of Autologous Cell Therapy by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Autologous Cell Therapy Market Status by Countries
5.1.1 North America Autologous Cell Therapy Sales by Countries (2013-2017)
5.1.2 North America Autologous Cell Therapy Revenue by Countries (2013-2017)
5.1.3 United States Autologous Cell Therapy Market Status (2013-2017)
5.1.4 Canada Autologous Cell Therapy Market Status (2013-2017)
5.1.5 Mexico Autologous Cell Therapy Market Status (2013-2017)
5.2 North America Autologous Cell Therapy Market Status by Manufacturers
5.3 North America Autologous Cell Therapy Market Status by Type (2013-2017)
5.3.1 North America Autologous Cell Therapy Sales by Type (2013-2017)
5.3.2 North America Autologous Cell Therapy Revenue by Type (2013-2017)
5.4 North America Autologous Cell Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Autologous Cell Therapy Market Status by Countries
6.1.1 Europe Autologous Cell Therapy Sales by Countries (2013-2017)
6.1.2 Europe Autologous Cell Therapy Revenue by Countries (2013-2017)
6.1.3 Germany Autologous Cell Therapy Market Status (2013-2017)
6.1.4 UK Autologous Cell Therapy Market Status (2013-2017)
6.1.5 France Autologous Cell Therapy Market Status (2013-2017)
6.1.6 Italy Autologous Cell Therapy Market Status (2013-2017)
6.1.7 Russia Autologous Cell Therapy Market Status (2013-2017)
6.1.8 Spain Autologous Cell Therapy Market Status (2013-2017)
6.1.9 Benelux Autologous Cell Therapy Market Status (2013-2017)
6.2 Europe Autologous Cell Therapy Market Status by Manufacturers
6.3 Europe Autologous Cell Therapy Market Status by Type (2013-2017)
6.3.1 Europe Autologous Cell Therapy Sales by Type (2013-2017)
6.3.2 Europe Autologous Cell Therapy Revenue by Type (2013-2017)
6.4 Europe Autologous Cell Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Autologous Cell Therapy Market Status by Countries
7.1.1 Asia Pacific Autologous Cell Therapy Sales by Countries (2013-2017)
7.1.2 Asia Pacific Autologous Cell Therapy Revenue by Countries (2013-2017)
7.1.3 China Autologous Cell Therapy Market Status (2013-2017)
7.1.4 Japan Autologous Cell Therapy Market Status (2013-2017)
7.1.5 India Autologous Cell Therapy Market Status (2013-2017)
7.1.6 Southeast Asia Autologous Cell Therapy Market Status (2013-2017)
7.1.7 Australia Autologous Cell Therapy Market Status (2013-2017)
7.2 Asia Pacific Autologous Cell Therapy Market Status by Manufacturers
7.3 Asia Pacific Autologous Cell Therapy Market Status by Type (2013-2017)
7.3.1 Asia Pacific Autologous Cell Therapy Sales by Type (2013-2017)
7.3.2 Asia Pacific Autologous Cell Therapy Revenue by Type (2013-2017)
7.4 Asia Pacific Autologous Cell Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Autologous Cell Therapy Market Status by Countries
8.1.1 Latin America Autologous Cell Therapy Sales by Countries (2013-2017)
8.1.2 Latin America Autologous Cell Therapy Revenue by Countries (2013-2017)
8.1.3 Brazil Autologous Cell Therapy Market Status (2013-2017)
8.1.4 Argentina Autologous Cell Therapy Market Status (2013-2017)
8.1.5 Colombia Autologous Cell Therapy Market Status (2013-2017)
8.2 Latin America Autologous Cell Therapy Market Status by Manufacturers
8.3 Latin America Autologous Cell Therapy Market Status by Type (2013-2017)
8.3.1 Latin America Autologous Cell Therapy Sales by Type (2013-2017)
8.3.2 Latin America Autologous Cell Therapy Revenue by Type (2013-2017)
8.4 Latin America Autologous Cell Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Autologous Cell Therapy Market Status by Countries
9.1.1 Middle East and Africa Autologous Cell Therapy Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Autologous Cell Therapy Revenue by Countries (2013-2017)
9.1.3 Middle East Autologous Cell Therapy Market Status (2013-2017)
9.1.4 Africa Autologous Cell Therapy Market Status (2013-2017)
9.2 Middle East and Africa Autologous Cell Therapy Market Status by Manufacturers
9.3 Middle East and Africa Autologous Cell Therapy Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Autologous Cell Therapy Sales by Type (2013-2017)
9.3.2 Middle East and Africa Autologous Cell Therapy Revenue by Type (2013-2017)
9.4 Middle East and Africa Autologous Cell Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF AUTOLOGOUS CELL THERAPY
10.1 Global Economy Situation and Trend Overview
10.2 Autologous Cell Therapy Downstream Industry Situation and Trend Overview
CHAPTER 11 AUTOLOGOUS CELL THERAPY MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Autologous Cell Therapy by Major Manufacturers
11.2 Production Value of Autologous Cell Therapy by Major Manufacturers
11.3 Basic Information of Autologous Cell Therapy by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Autologous Cell Therapy Major Manufacturer
11.3.2 Employees and Revenue Level of Autologous Cell Therapy Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 AUTOLOGOUS CELL THERAPY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 BioTime, Inc.
12.1.1 Company profile
12.1.2 Representative Autologous Cell Therapy Product
12.1.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of BioTime, Inc.
12.2 BrainStorm Cell Therapeutics
12.2.1 Company profile
12.2.2 Representative Autologous Cell Therapy Product
12.2.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of BrainStorm Cell Therapeutics
12.3 Caladrius Biosciences, Inc.
12.3.1 Company profile
12.3.2 Representative Autologous Cell Therapy Product
12.3.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Caladrius Biosciences, Inc.
12.4 Fibrocell Science, Inc.
12.4.1 Company profile
12.4.2 Representative Autologous Cell Therapy Product
12.4.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Fibrocell Science, Inc.
12.5 Opexa Therapeutics, Inc.
12.5.1 Company profile
12.5.2 Representative Autologous Cell Therapy Product
12.5.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Opexa Therapeutics, Inc.
12.6 Pharmicell Co., Inc.
12.6.1 Company profile
12.6.2 Representative Autologous Cell Therapy Product
12.6.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Pharmicell Co., Inc.
12.7 Regeneus Ltd.
12.7.1 Company profile
12.7.2 Representative Autologous Cell Therapy Product
12.7.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Regeneus Ltd.
12.8 TiGenix NV
12.8.1 Company profile
12.8.2 Representative Autologous Cell Therapy Product
12.8.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of TiGenix NV
12.9 TxCell SA
12.9.1 Company profile
12.9.2 Representative Autologous Cell Therapy Product
12.9.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of TxCell SA
12.10 U.S. Stem Cell, Inc.
12.10.1 Company profile
12.10.2 Representative Autologous Cell Therapy Product
12.10.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of U.S. Stem Cell, Inc.
12.11 Vericel Corporation
12.11.1 Company profile
12.11.2 Representative Autologous Cell Therapy Product
12.11.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Vericel Corporation
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF AUTOLOGOUS CELL THERAPY
13.1 Industry Chain of Autologous Cell Therapy
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF AUTOLOGOUS CELL THERAPY
14.1 Cost Structure Analysis of Autologous Cell Therapy
14.2 Raw Materials Cost Analysis of Autologous Cell Therapy
14.3 Labor Cost Analysis of Autologous Cell Therapy
14.4 Manufacturing Expenses Analysis of Autologous Cell Therapy
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of Autologous Cell Therapy in This Report
1.2 Commercial Types of Autologous Cell Therapy
1.2.1 Bone Marrow
1.2.2 Epidermis
1.3 Downstream Application of Autologous Cell Therapy
1.3.1 Neurology
1.3.2 Orthopedics
1.3.3 Cancer
1.3.4 Wound Healing
1.3.5 CVD
1.3.6 Autoimmune
1.3.7 Others
1.4 Development History of Autologous Cell Therapy
1.5 Market Status and Trend of Autologous Cell Therapy 2013-2023
1.5.1 Global Autologous Cell Therapy Market Status and Trend 2013-2023
1.5.2 Regional Autologous Cell Therapy Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Autologous Cell Therapy 2013-2017
2.2 Sales Market of Autologous Cell Therapy by Regions
2.2.1 Sales Volume of Autologous Cell Therapy by Regions
2.2.2 Sales Value of Autologous Cell Therapy by Regions
2.3 Production Market of Autologous Cell Therapy by Regions
2.4 Global Market Forecast of Autologous Cell Therapy 2018-2023
2.4.1 Global Market Forecast of Autologous Cell Therapy 2018-2023
2.4.2 Market Forecast of Autologous Cell Therapy by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Autologous Cell Therapy by Types
3.2 Sales Value of Autologous Cell Therapy by Types
3.3 Market Forecast of Autologous Cell Therapy by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Autologous Cell Therapy by Downstream Industry
4.2 Global Market Forecast of Autologous Cell Therapy by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Autologous Cell Therapy Market Status by Countries
5.1.1 North America Autologous Cell Therapy Sales by Countries (2013-2017)
5.1.2 North America Autologous Cell Therapy Revenue by Countries (2013-2017)
5.1.3 United States Autologous Cell Therapy Market Status (2013-2017)
5.1.4 Canada Autologous Cell Therapy Market Status (2013-2017)
5.1.5 Mexico Autologous Cell Therapy Market Status (2013-2017)
5.2 North America Autologous Cell Therapy Market Status by Manufacturers
5.3 North America Autologous Cell Therapy Market Status by Type (2013-2017)
5.3.1 North America Autologous Cell Therapy Sales by Type (2013-2017)
5.3.2 North America Autologous Cell Therapy Revenue by Type (2013-2017)
5.4 North America Autologous Cell Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Autologous Cell Therapy Market Status by Countries
6.1.1 Europe Autologous Cell Therapy Sales by Countries (2013-2017)
6.1.2 Europe Autologous Cell Therapy Revenue by Countries (2013-2017)
6.1.3 Germany Autologous Cell Therapy Market Status (2013-2017)
6.1.4 UK Autologous Cell Therapy Market Status (2013-2017)
6.1.5 France Autologous Cell Therapy Market Status (2013-2017)
6.1.6 Italy Autologous Cell Therapy Market Status (2013-2017)
6.1.7 Russia Autologous Cell Therapy Market Status (2013-2017)
6.1.8 Spain Autologous Cell Therapy Market Status (2013-2017)
6.1.9 Benelux Autologous Cell Therapy Market Status (2013-2017)
6.2 Europe Autologous Cell Therapy Market Status by Manufacturers
6.3 Europe Autologous Cell Therapy Market Status by Type (2013-2017)
6.3.1 Europe Autologous Cell Therapy Sales by Type (2013-2017)
6.3.2 Europe Autologous Cell Therapy Revenue by Type (2013-2017)
6.4 Europe Autologous Cell Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Autologous Cell Therapy Market Status by Countries
7.1.1 Asia Pacific Autologous Cell Therapy Sales by Countries (2013-2017)
7.1.2 Asia Pacific Autologous Cell Therapy Revenue by Countries (2013-2017)
7.1.3 China Autologous Cell Therapy Market Status (2013-2017)
7.1.4 Japan Autologous Cell Therapy Market Status (2013-2017)
7.1.5 India Autologous Cell Therapy Market Status (2013-2017)
7.1.6 Southeast Asia Autologous Cell Therapy Market Status (2013-2017)
7.1.7 Australia Autologous Cell Therapy Market Status (2013-2017)
7.2 Asia Pacific Autologous Cell Therapy Market Status by Manufacturers
7.3 Asia Pacific Autologous Cell Therapy Market Status by Type (2013-2017)
7.3.1 Asia Pacific Autologous Cell Therapy Sales by Type (2013-2017)
7.3.2 Asia Pacific Autologous Cell Therapy Revenue by Type (2013-2017)
7.4 Asia Pacific Autologous Cell Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Autologous Cell Therapy Market Status by Countries
8.1.1 Latin America Autologous Cell Therapy Sales by Countries (2013-2017)
8.1.2 Latin America Autologous Cell Therapy Revenue by Countries (2013-2017)
8.1.3 Brazil Autologous Cell Therapy Market Status (2013-2017)
8.1.4 Argentina Autologous Cell Therapy Market Status (2013-2017)
8.1.5 Colombia Autologous Cell Therapy Market Status (2013-2017)
8.2 Latin America Autologous Cell Therapy Market Status by Manufacturers
8.3 Latin America Autologous Cell Therapy Market Status by Type (2013-2017)
8.3.1 Latin America Autologous Cell Therapy Sales by Type (2013-2017)
8.3.2 Latin America Autologous Cell Therapy Revenue by Type (2013-2017)
8.4 Latin America Autologous Cell Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Autologous Cell Therapy Market Status by Countries
9.1.1 Middle East and Africa Autologous Cell Therapy Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Autologous Cell Therapy Revenue by Countries (2013-2017)
9.1.3 Middle East Autologous Cell Therapy Market Status (2013-2017)
9.1.4 Africa Autologous Cell Therapy Market Status (2013-2017)
9.2 Middle East and Africa Autologous Cell Therapy Market Status by Manufacturers
9.3 Middle East and Africa Autologous Cell Therapy Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Autologous Cell Therapy Sales by Type (2013-2017)
9.3.2 Middle East and Africa Autologous Cell Therapy Revenue by Type (2013-2017)
9.4 Middle East and Africa Autologous Cell Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF AUTOLOGOUS CELL THERAPY
10.1 Global Economy Situation and Trend Overview
10.2 Autologous Cell Therapy Downstream Industry Situation and Trend Overview
CHAPTER 11 AUTOLOGOUS CELL THERAPY MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Autologous Cell Therapy by Major Manufacturers
11.2 Production Value of Autologous Cell Therapy by Major Manufacturers
11.3 Basic Information of Autologous Cell Therapy by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Autologous Cell Therapy Major Manufacturer
11.3.2 Employees and Revenue Level of Autologous Cell Therapy Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 AUTOLOGOUS CELL THERAPY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 BioTime, Inc.
12.1.1 Company profile
12.1.2 Representative Autologous Cell Therapy Product
12.1.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of BioTime, Inc.
12.2 BrainStorm Cell Therapeutics
12.2.1 Company profile
12.2.2 Representative Autologous Cell Therapy Product
12.2.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of BrainStorm Cell Therapeutics
12.3 Caladrius Biosciences, Inc.
12.3.1 Company profile
12.3.2 Representative Autologous Cell Therapy Product
12.3.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Caladrius Biosciences, Inc.
12.4 Fibrocell Science, Inc.
12.4.1 Company profile
12.4.2 Representative Autologous Cell Therapy Product
12.4.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Fibrocell Science, Inc.
12.5 Opexa Therapeutics, Inc.
12.5.1 Company profile
12.5.2 Representative Autologous Cell Therapy Product
12.5.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Opexa Therapeutics, Inc.
12.6 Pharmicell Co., Inc.
12.6.1 Company profile
12.6.2 Representative Autologous Cell Therapy Product
12.6.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Pharmicell Co., Inc.
12.7 Regeneus Ltd.
12.7.1 Company profile
12.7.2 Representative Autologous Cell Therapy Product
12.7.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Regeneus Ltd.
12.8 TiGenix NV
12.8.1 Company profile
12.8.2 Representative Autologous Cell Therapy Product
12.8.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of TiGenix NV
12.9 TxCell SA
12.9.1 Company profile
12.9.2 Representative Autologous Cell Therapy Product
12.9.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of TxCell SA
12.10 U.S. Stem Cell, Inc.
12.10.1 Company profile
12.10.2 Representative Autologous Cell Therapy Product
12.10.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of U.S. Stem Cell, Inc.
12.11 Vericel Corporation
12.11.1 Company profile
12.11.2 Representative Autologous Cell Therapy Product
12.11.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Vericel Corporation
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF AUTOLOGOUS CELL THERAPY
13.1 Industry Chain of Autologous Cell Therapy
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF AUTOLOGOUS CELL THERAPY
14.1 Cost Structure Analysis of Autologous Cell Therapy
14.2 Raw Materials Cost Analysis of Autologous Cell Therapy
14.3 Labor Cost Analysis of Autologous Cell Therapy
14.4 Manufacturing Expenses Analysis of Autologous Cell Therapy
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
